Role of HMG-CoA reductase inhibitors with curative radiotherapy in men with prostate cancer

le of HMG-CoA reductase inhibitors with curative radiotherapy in men with prostate cancer Review (2348) Total Article Views Authors: Solanki AA, Liauw SL Published Date June 2011 Volume 2011:3 Pages 95 - 104 DOI: http://dx.doi.org/10.2147/RRU.S14245 Abhishek A Solanki, Stanley L Liauw Department of Radiation and Cellular Oncology, University of Chicago Medical Center, Chicago, IL, USA Abstract: Brachytherapy and external beam radiotherapy are effective and commonly used treatment modalities in men with localized prostate cancer. In this review, we explore the role of radiation therapy in the curative management of prostate cancer, including the use of conformal therapeutic techniques to allow for the escalation of radiation doses to tumor, along with the use of combined radiation and hormonal therapy to enhance disease outcomes in men with aggressive disease. We also review the possible anticancer role of HMG-CoA reductase inhibiting agents (statins) in men with prostate cancer. Laboratory evidence suggests that statins may have antineoplastic effects when used alone and may sensitize cells to radiation therapy when given in combination. We explore the biologic basis for an anticancer effect and the clinical evidence suggesting statins may aid in improving outcomes with radiation therapy for localized prostate cancer.